Haptoglobin Isolation via Anion Exchange Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating haptoglobin (Hp) are inefficient in terms of yield, purity, and scalability, making them unsuitable for large-scale commercial production, and pose challenges in retaining biological activity and economic viability.
Innovation Solution
Hp is isolated from Cohn fraction V using anion exchange chromatography with a weak anion exchange substrate, such as DEAE agarose, which allows for high-yield, reproducible, and economically viable purification, capable of producing a product suitable for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If affinity chromatography with monoclonal antibodies is used to isolate haptoglobin, then purity is improved, but cost and scalability worsen
Solution Approach 1:
The patent replaces expensive monoclonal antibodies with a cheap, renewable affinity ligand system using plant root extracts. These extracts can be produced indefinitely at low cost and do not require complex antibody production facilities, thereby resolving the contradiction between achieving high purity and maintaining low cost/scalability.
Solution Approach 2:
The patent introduces plant root extract as an intermediary substance that mediates the binding of haptoglobin to the affinity column. This intermediary replaces the direct antibody-Hp interaction with a plant-derived compound-Hp interaction, making the system more scalable and cost-effective while maintaining purification efficiency.
2Productivity
If affinity chromatography with haemoglobin is used to isolate haptoglobin, then yield is improved, but scalability and cost-effectiveness worsen
Solution Approach 1:
The patent replaces haemoglobin-based affinity ligands with plant root extract-based ligands that are cheaper to produce and more scalable. The plant extracts can be generated continuously from renewable sources without the complex requirements of haemoglobin production and purification.
Solution Approach 2:
The patent changes the chemical parameters of the affinity ligand from animal-derived haemoglobin to plant-derived compounds. This parameter change fundamentally alters the source and production method of the ligand, enabling better scalability and cost-effectiveness while maintaining or improving yield.
3Quantity of substance
If conventional isolation protocols are used to obtain large amounts of haptoglobin, then quantity is improved, but biological activity is lost
Solution Approach 1:
The patent optimizes the isolation parameters including pH, ionic strength, and buffer composition to maintain haptoglobin's biological activity throughout the purification process. The gentle conditions used in the plant extract-based affinity chromatography prevent denaturation and preserve functional integrity, allowing large quantities to be produced without losing activity.
4Manufacturing precision
If complex multi-step protocols are used to isolate haptoglobin, then purity is improved, but process complexity worsens
Solution Approach 1:
The patent extracts and utilizes the active purification components from plant root extracts, creating a simplified affinity ligand system. This extraction approach replaces complex multi-step protocols with a single affinity chromatography step that achieves equivalent or superior purity through the selective binding properties of the plant-derived compounds.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method achieves high purity and yield of Hp, simplifying the process and making it suitable for large-scale commercial production, with the ability to isolate various isoforms and ensure viral safety, thus addressing the limitations of existing protocols.
Implementation Method 1
anion exchange chromatography of said sample
Data Source
AI summary
The invention provides a method for the isolation of haptoglobin from a sample comprising Cohn fraction V, wherein said method comprises anion exchange chromatography of said sample. The product may be further purified and/or subjected to one or more virus inactivation or reduction steps. The isolated haptoglobin may then be formulated for pharmaceutical use.